

Supplemental Table 1: Characteristics of study population, stratifying by diagnosis of colorectal cancer

Characteristic	No colorectal cancer (n = 6.669) %	Colorectal cancer (n = 154) %	p-value
Median age (in years) (IQR)	48 (34 – 62)	57 (45 – 66)	< 0.001
Median age at first IBD diagnosis code (SD) (in years)	38 (26 – 53)	51 (39 – 62)	< 0.001
Duration of follow-up after first IBD code [Median (IQR)] (years)	8 (5 – 12)	5 (2 – 8)	< 0.001
Sex			0.002
Female	55	42	
Male	45	58	
Race			0.90
White	88	87	
Non-white	12	13	
Type of IBD			
Crohn's disease	48	46	
Ulcerative colitis	52	54	
Primary Sclerosing Cholangitis	2	8	0.001
Ever immunomodulator use‡	29	21	0.04
Ever biologic use‡	14	10	0.14
Died	5	29	< 0.001

IQR – interquartile range; IBD – inflammatory bowel diseases;

‡ Immunomodulators comprise azathioprine, 6-mercaptopurine (6-MP), methotrexate) while biologics include infliximab, adalimumab, and certolizumab pegol